{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:26:50Z","timestamp":1788672410927,"version":"build-2803163510"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10067-025-07711-6","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T21:38:12Z","timestamp":1759786692000},"page":"4451-4469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of antimalarials in lupus nephritis: a narrative review"],"prefix":"10.1007","volume":"44","author":[{"given":"Tarek Carlos","family":"Salman-Monte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"7711_CR1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR (2024) Systemic lupus erythematosus: a review. JAMA 331:1480\u20131491","journal-title":"JAMA"},{"key":"7711_CR2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, Svenungsson E, Peterson J, Clarke AE, Ramsey-Goldman R (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17:515\u2013532","journal-title":"Nat Rev Rheumatol"},{"key":"7711_CR3","doi-asserted-by":"crossref","unstructured":"R. Cort\u00e9s Verd\u00fa, J.M. Pego-Reigosa, D. Seoane-Mato, M. Morcillo Valle, D. Palma S\u00e1nchez, M.J. Moreno Mart\u00ednez, M. Mayor Gonz\u00e1lez, J. Atxotegi S\u00e1enz de Buruaga, I. Urionag\u00fcena Onaindia, B.A. Blanco C\u00e1ceres, L. Silva-Fern\u00e1ndez, F. Sivera, F.J. Blanco, C. S\u00e1nchez-Piedra, F. D\u00edaz-Gonz\u00e1lez and S. Bustabad, Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?, Rheumatology (Oxford) 59 (2020) 2556\u20132562.","DOI":"10.1093\/rheumatology\/kez668"},{"key":"7711_CR4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.nefro.2022.12.008","volume":"43","author":"C Moriano","year":"2023","unstructured":"Moriano C, Bellido Pastrana D, San Rom\u00e1n Guti\u00e9rrez C, Rodr\u00edguez E (2023) Evoluci\u00f3n del diagn\u00f3stico y tratamiento de la nefritis l\u00fapica en Espa\u00f1a. Nefrologia 43:668\u2013675","journal-title":"Nefrologia"},{"key":"7711_CR5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"K.D.I.G.O.K.L.N.W. Group","year":"2024","unstructured":"K.D.I.G.O.K.L.N.W. Group (2024) Kdigo 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 105:S1-s69","journal-title":"Kidney Int"},{"key":"7711_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","volume":"15","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241\u2013250","journal-title":"J Am Soc Nephrol"},{"key":"7711_CR7","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6:7","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"7711_CR8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT (2020) 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(7):713\u2013723","journal-title":"Ann Rheum Dis"},{"key":"7711_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, D\u00f6rner T, Furie RA, Gladman DD, Houssiau FA, In\u00eas LS, Jayne D, Kouloumas M, Kov\u00e1cs L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329","journal-title":"Ann Rheum Dis"},{"key":"7711_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nefroe.2023.05.006","volume":"43","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera JE, Garc\u00eda-Carro C, \u00c1vila AI, Espino M, Espinosa M, Fern\u00e1ndez-Ju\u00e1rez G, Fulladosa X, Goicoechea M, Mac\u00eda M, Morales E, Porras LFQ, Praga M (2023) Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis. Nefrolog\u00eda (English Edition) 43:6\u201347","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"7711_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae254","author":"F Caravaca-Font\u00e1n","year":"2024","unstructured":"Caravaca-Font\u00e1n F, Yandian F, Fervenza FC (2024) Hydroxychloroquine for all patients with lupus nephritis: no. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfae254","journal-title":"Nephrol Dial Transplant"},{"key":"7711_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae280","author":"M Pappa","year":"2024","unstructured":"Pappa M, Boumpas DT, Fanouriakis A (2024) Hydroxychloroquine for all patients with lupus nephritis: yes. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfae280","journal-title":"Nephrol Dial Transplant"},{"issue":"2023","key":"7711_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4269\/ajtmh.22-0404","volume":"108","author":"LH Miller","year":"2023","unstructured":"Miller LH, Rojas-Jaimes J, Low LM, Corbellini G (2023) What historical records teach us about the discovery of quinine. Am J Trop Med Hyg 108(2023):7\u201311","journal-title":"Am J Trop Med Hyg"},{"key":"7711_CR14","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211073001","volume":"14","author":"A Dima","year":"2022","unstructured":"Dima A, Jurcut C, Chasset F, Felten R, Arnaud L (2022) Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 14:1759720x211073001","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7711_CR15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s40620-023-01733-6","volume":"36","author":"IR Rao","year":"2023","unstructured":"Rao IR, Kolakemar A, Shenoy SV, Prabhu RA, Nagaraju SP, Rangaswamy D, Bhojaraja MV (2023) Hydroxychloroquine in nephrology: current status and future directions. J Nephrol 36:2191\u20132208","journal-title":"J Nephrol"},{"key":"7711_CR16","unstructured":"FDA, PLAQUENIL. Highlights of prescribing information, in: Editor (Ed.)^(Eds.), Book PLAQUENIL. Highlights of prescribing information, 2021, pp."},{"key":"7711_CR17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.therap.2021.01.056","volume":"76","author":"N Zahr","year":"2021","unstructured":"Zahr N, Urien S, Llopis B, Pourcher V, Paccoud O, Bleibtreu A, Mayaux J, Gandjbakhch E, Hekimian G, Combes A, Benveniste O, Saadoun D, Allenbach Y, Pinna B, Cacoub P, Funck-Brentano C, Salem JE (2021) Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie 76:285\u2013295","journal-title":"Therapie"},{"issue":"2006","key":"7711_CR18","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Franc\u00e8s C, Wechsler B, Huong du LT, Ghillani P, Musset L, Lechat P, Piette JC (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54(2006):3284\u20133290","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"7711_CR19","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1177\/0961203396005001041","volume":"5","author":"DE Furst","year":"1996","unstructured":"Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5(Suppl 1):S11\u2013S15","journal-title":"Lupus"},{"key":"7711_CR20","unstructured":"AEMPS, Dolquine. Summary of Product Characteristics in: Editor (Ed.)^(Eds.), Book Dolquine. Summary of Product Characteristics 2021, pp."},{"key":"7711_CR21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"SE Tett","year":"1989","unstructured":"Tett SE, Cutler DJ, Day RO, Brown KF (1989) Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 27:771\u2013779","journal-title":"Br J Clin Pharmacol"},{"key":"7711_CR22","first-page":"531","volume":"13","author":"M Babayeva","year":"2020","unstructured":"Babayeva M, Loewy Z (2020) Repurposing drugs for COVID-19: pharmacokinetics and pharmacogenomics of chloroquine and hydroxychloroquine. Pharmgenomics Pers Med 13:531\u2013542","journal-title":"Pharmgenomics Pers Med"},{"key":"7711_CR23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-199631040-00003","volume":"31","author":"J Ducharme","year":"1996","unstructured":"Ducharme J, Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31:257\u2013274","journal-title":"Clin Pharmacokinet"},{"key":"7711_CR24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2020.100159","volume":"2","author":"M Louchet","year":"2020","unstructured":"Louchet M, Sibiude J, Peytavin G, Picone O, Tr\u00e9luyer JM, Mandelbrot L (2020) Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol MFM 2:100159","journal-title":"Am J Obstet Gynecol MFM"},{"key":"7711_CR25","first-page":"1127","volume":"21","author":"S Rendic","year":"2020","unstructured":"Rendic S, Guengerich FP (2020) Metabolism and interactions of chloroquine and hydroxychloroquine with human cytochrome P450 enzymes and drug transporters. Curr Drug Metab 21:1127\u20131135","journal-title":"Curr Drug Metab"},{"key":"7711_CR26","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 3652, Hydroxychloroquine., in: Editor (Ed.)^(Eds.), Book National Center for Biotechnology Information. PubChem Compound Summary for CID 3652, Hydroxychloroquine., 2024, pp."},{"key":"7711_CR27","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.01835-10","volume":"55","author":"F M\u00fcller","year":"2011","unstructured":"M\u00fcller F, K\u00f6nig J, Glaeser H, Schmidt I, Zolk O, Fromm MF, Maas R (2011) Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 55:3091\u20133098","journal-title":"Antimicrob Agents Chemother"},{"key":"7711_CR28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155\u2013166","journal-title":"Nat Rev Rheumatol"},{"key":"7711_CR29","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M (2020) Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med 12:e12476","journal-title":"EMBO Mol Med"},{"key":"7711_CR30","first-page":"718","volume":"7","author":"SJ Lee","year":"2011","unstructured":"Lee SJ, Silverman E, Bargman JM (2011) The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 7:718\u2013729","journal-title":"Nat Rev Nephrol"},{"key":"7711_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2006.10.018","volume":"26","author":"D Schmid","year":"2007","unstructured":"Schmid D, Pypaert M, M\u00fcnz C (2007) Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity 26:79\u201392","journal-title":"Immunity"},{"key":"7711_CR32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbamcr.2008.07.014","volume":"1793","author":"E Eeva-Liisa","year":"2009","unstructured":"Eeva-Liisa E, Paul S (2009) Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1793:664\u2013673","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"7711_CR33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F (2018) Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14:1435\u20131455","journal-title":"Autophagy"},{"key":"7711_CR34","volume":"13","author":"T Duan","year":"2022","unstructured":"Duan T, Du Y, Xing C, Wang HY, Wang RF (2022) Toll-like receptor signaling and its role in cell-mediated immunity. Front Immunol 13:812774","journal-title":"Front Immunol"},{"key":"7711_CR35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","volume":"36","author":"YW Wu","year":"2015","unstructured":"Wu YW, Tang W, Zuo JP (2015) Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin 36:1395\u20131407","journal-title":"Acta Pharmacol Sin"},{"key":"7711_CR36","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794\u20134804","journal-title":"J Immunol"},{"issue":"2015","key":"7711_CR37","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","volume":"194","author":"J An","year":"2015","unstructured":"An J, Woodward JJ, Sasaki T, Minie M, Elkon KB (2015) Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunol 194(2015):4089\u20134093","journal-title":"J Immunol"},{"key":"7711_CR38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","volume":"76","author":"N M\u00fcller-Calleja","year":"2017","unstructured":"M\u00fcller-Calleja N, Manukyan D, Canisius A, Strand D, Lackner KJ (2017) Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis 76:891\u2013897","journal-title":"Ann Rheum Dis"},{"key":"7711_CR39","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","volume":"95","author":"FD Goldman","year":"2000","unstructured":"Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 95:3460\u20133466","journal-title":"Blood"},{"key":"7711_CR40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000484955","volume":"44","author":"N An","year":"2017","unstructured":"An N, Chen Y, Wang C, Yang C, Wu ZH, Xue J, Ye L, Wang S, Liu HF, Pan Q (2017) Chloroquine autophagic inhibition rebalances Th17\/Treg-mediated immunity and ameliorates systemic lupus erythematosus. Cell Physiol Biochem 44:412\u2013422","journal-title":"Cell Physiol Biochem"},{"key":"7711_CR41","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3899\/jrheum.170737","volume":"45","author":"J Yang","year":"2018","unstructured":"Yang J, Yang X, Yang J, Li M (2018) Hydroxychloroquine inhibits the differentiation of Th17 cells in systemic lupus erythematosus. J Rheumatol 45:818\u2013826","journal-title":"J Rheumatol"},{"key":"7711_CR42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0306-3623(97)00269-3","volume":"30","author":"J Bondeson","year":"1998","unstructured":"Bondeson J, Sundler R (1998) Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 30:357\u2013366","journal-title":"Gen Pharmacol"},{"key":"7711_CR43","volume":"7","author":"ME Schroeder","year":"2017","unstructured":"Schroeder ME, Russo S, Costa C, Hori J, Tiscornia I, Bollati-Fogol\u00edn M, Zamboni DS, Ferreira G, Cairoli E, Hill M (2017) Pro-inflammatory Ca(++)-activated K(+) channels are inhibited by hydroxychloroquine. Sci Rep 7:1892","journal-title":"Sci Rep"},{"key":"7711_CR44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3899\/jrheum.200726","volume":"48","author":"WM Lambers","year":"2021","unstructured":"Lambers WM, Westra J, Bootsma H, de Leeuw K (2021) Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol 48:847\u2013851","journal-title":"J Rheumatol"},{"key":"7711_CR45","volume":"19","author":"SF Wu","year":"2017","unstructured":"Wu SF, Chang CB, Hsu JM, Lu MC, Lai NS, Li C, Tung CH (2017) Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther 19:183","journal-title":"Arthritis Res Ther"},{"key":"7711_CR46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1196\/annals.1422.005","volume":"1108","author":"L Sailler","year":"2007","unstructured":"Sailler L, Puissant B, M\u00e9liani P, Castex JO, Saivin S, Adoue D, Fournie B, Arlet P, Montastruc JL, Lapeyre-Mestre M, Pourrat J, Blancher A (2007) Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci 1108:41\u201350","journal-title":"Ann N Y Acad Sci"},{"key":"7711_CR47","first-page":"1124","volume":"159","author":"A Wozniacka","year":"2008","unstructured":"Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A (2008) The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol 159:1124\u20131130","journal-title":"Br J Dermatol"},{"key":"7711_CR48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0961203306075384","volume":"16","author":"A Wozniacka","year":"2007","unstructured":"Wozniacka A, Lesiak A, Narbutt J, Kobos J, Pavel S, Sysa-Jedrzejowska A (2007) Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus. Lupus 16:89\u201394","journal-title":"Lupus"},{"key":"7711_CR49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2340\/0001555575228231","volume":"75","author":"G Sj\u00f6lin-Forsberg","year":"1995","unstructured":"Sj\u00f6lin-Forsberg G, Berne B, Eggelte TA, Karlsson-Parra A (1995) In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 75:228\u2013231","journal-title":"Acta Derm Venereol"},{"key":"7711_CR50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0961203309356455","volume":"19","author":"A Lesiak","year":"2010","unstructured":"Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, W\u00f3zniacka A (2010) Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19:683\u2013688","journal-title":"Lupus"},{"key":"7711_CR51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00403-018-1811-2","volume":"310","author":"G Ertugrul","year":"2018","unstructured":"Ertugrul G, Keles D, Oktay G, Aktan S (2018) Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. Arch Dermatol Res 310:173\u2013179","journal-title":"Arch Dermatol Res"},{"key":"7711_CR52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2249.2006.03070.x","volume":"144","author":"WU Kim","year":"2006","unstructured":"Kim WU, Yoo SA, Min SY, Park SH, Koh HS, Song SW, Cho CS (2006) Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 144:503\u2013511","journal-title":"Clin Exp Immunol"},{"key":"7711_CR53","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4049\/jimmunol.158.4.1872","volume":"158","author":"F Potvin","year":"1997","unstructured":"Potvin F, Petitclerc E, Marceau F, Poubelle PE (1997) Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immunol 158:1872\u20131879","journal-title":"J Immunol"},{"key":"7711_CR54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.2001.02553.x","volume":"112","author":"L Lagneaux","year":"2001","unstructured":"Lagneaux L, Delforge A, Carlier S, Massy M, Bernier M, Bron D (2001) Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br J Haematol 112:344\u2013352","journal-title":"Br J Haematol"},{"key":"7711_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021331","author":"DJ Arachchillage","year":"2023","unstructured":"Arachchillage DJ, Laffan M, Pericleous C (2023) Hydroxychloroquine as an immunomodulatory and antithrombotic treatment in antiphospholipid syndrome. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24021331","journal-title":"Int J Mol Sci"},{"key":"7711_CR56","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","volume":"112","author":"JH Rand","year":"2008","unstructured":"Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112:1687\u20131695","journal-title":"Blood"},{"key":"7711_CR57","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0002-9343(87)90237-3","volume":"82","author":"PE Barr\u00e9","year":"1987","unstructured":"Barr\u00e9 PE, Gascon-Barr\u00e9 M, Meakins JL, Goltzman D (1987) Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med 82:1259\u20131262","journal-title":"Am J Med"},{"key":"7711_CR58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20\u201328","journal-title":"Ann Rheum Dis"},{"key":"7711_CR59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","volume":"16","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli C, Moroni G (2017) Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 16:411\u2013419","journal-title":"Expert Opin Drug Saf"},{"key":"7711_CR60","doi-asserted-by":"crossref","unstructured":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus, N Engl J Med 324 (1991) 150\u20134.","DOI":"10.1056\/NEJM199101173240303"},{"key":"7711_CR61","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1177\/09612033221129774","volume":"31","author":"T Cai","year":"2022","unstructured":"Cai T, Zhao J, Yang Y, Jiang Y, Zhang JA (2022) Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies. Lupus 31:1714\u20131725","journal-title":"Lupus"},{"key":"7711_CR62","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarc\u00f3n","year":"2007","unstructured":"Alarc\u00f3n GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Al\u00e9n J, Bastian HM, Vil\u00e1 LM, Reveille JD (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168\u20131172","journal-title":"Ann Rheum Dis"},{"key":"7711_CR63","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3899\/jrheum.120572","volume":"40","author":"PS Akhavan","year":"2013","unstructured":"Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR (2013) The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 40:831\u2013841","journal-title":"J Rheumatol"},{"key":"7711_CR64","first-page":"1473","volume":"52","author":"B.J. Fessler, G.S. Alarcon, G. McGwin, Jr., J. Roseman, H.M. Bastian, A.W. Friedman, B.A. Baethge, L. Vila, J.D. Reveille and L.S. Group","year":"2005","unstructured":"B.J. Fessler, G.S. Alarcon, G. McGwin, Jr., J. Roseman, H.M. Bastian, A.W. Friedman, B.A. Baethge, L. Vila, J.D. Reveille and L.S. Group (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, Arthritis Rheum 52:1473\u20131480","journal-title":"Association of hydroxychloroquine use with reduced risk of damage accrual, Arthritis Rheum"},{"key":"7711_CR65","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","volume":"11","author":"G Ruiz-Irastorza","year":"2009","unstructured":"Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11:R109","journal-title":"Arthritis Res Ther"},{"key":"7711_CR66","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/art.27300","volume":"62","author":"SK Shinjo","year":"2010","unstructured":"Shinjo SK, Bonf\u00e1 E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, Brenol JC, Chac\u00f3n-Diaz R, Neira OJ, Berbotto GA, De La Torre IG, Acevedo-V\u00e1zquez EM, Massardo L, Barile-Fabris LA, Caeiro F, Silveira LH, Sato EI, Buliubasich S, Alarc\u00f3n GS, Pons-Estel BA (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62:855\u2013862","journal-title":"Arthritis Rheum"},{"key":"7711_CR67","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/ker514","volume":"51","author":"GJ Pons-Estel","year":"2012","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, Hachuel L, Boggio G, Wojdyla D, Pascual-Ramos V, Soriano ER, Saurit V, Cavalcanti FS, Guzman RA, Guibert-Toledano M, Sauza Del Pozo MJ, Amigo MC, Alva M, Esteva-Spinetti MH, Pons-Estel BA (2012) Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology (Oxford) 51:1293\u20131298","journal-title":"Rheumatology (Oxford)"},{"key":"7711_CR68","first-page":"95","volume":"32","author":"ASMW Tsang","year":"2014","unstructured":"Tsang ASMW, Bultink IE, Voskuyl AE (2014) Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. Clin Exp Rheumatol 32:95\u2013100","journal-title":"Clin Exp Rheumatol"},{"key":"7711_CR69","doi-asserted-by":"crossref","unstructured":"M. Galindo-Izquierdo, E. Rodriguez-Almaraz, J.M. Pego-Reigosa, F.J. Lopez-Longo, J. Calvo-Alen, A. Olive, A. Fernandez-Nebro, V. Martinez-Taboada, P. Vela-Casasempere, M. Freire, F.J. Narvaez, J. Rosas, M. Ibanez-Barcelo, E. Uriarte, E. Tomero, A. Zea, L. Horcada, V. Torrente, I. Castellvi, J. Calvet, R. Menor-Almagro, M.A.A. Zamorano, E. Raya, E. Diez-Alvarez, T. Vazquez-Rodriguez, P. Garcia de la Pena, A. Movasat, J.L. Andreu, P. Richi, C. Marras, C. Montilla-Morales, B. Hernandez-Cruz, J.L. Marenco de la Fuente, M. Gantes, E. Ucar, J.J. Alegre-Sancho, J. Manero, J. Ibanez-Ruan, M. Rodriguez-Gomez, V. Quevedo, J. Hernandez-Beriain, L. Silva-Fernandez, F. Alonso, S. Perez, I. Rua-Figueroa and f.t.S.S.o.R.S.A.D.S.G. Relesser Group, Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER), Medicine (Baltimore) 95 (2016) e2891.","DOI":"10.1097\/MD.0000000000002891"},{"key":"7711_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa142.P0442","author":"A Ribas","year":"2020","unstructured":"Ribas A, Galcer\u00e1n I, Out\u00f3n S, Salman T, Barrios C, Ochoa AS, Buxeda A, Sans L, Pascual J, Rodriguez E (2020) P0442related factors in the development of lupus nephritis in patients with systemic lupus erythematosus. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaa142.P0442","journal-title":"Nephrol Dial Transplant"},{"key":"7711_CR71","first-page":"80","volume":"7","author":"E Tsakonas","year":"1998","unstructured":"Tsakonas E, Joseph L, Esdaile JM, Choquette D, Sen\u00e9cal JL, Cividino A, Danoff D, Osterland CK, Yeadon C, Smith CD (1998) A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group, Lupus 7:80\u201385","journal-title":"The Canadian Hydroxychloroquine Study Group, Lupus"},{"key":"7711_CR72","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","volume":"15","author":"N Kasitanon","year":"2006","unstructured":"Kasitanon N, Fine DM, Haas M, Magder LS, Petri M (2006) Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15:366\u2013370","journal-title":"Lupus"},{"key":"7711_CR73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1191\/0961203306lu2271oa","volume":"15","author":"CE Barber","year":"2006","unstructured":"Barber CE, Geldenhuys L, Hanly JG (2006) Sustained remission of lupus nephritis. Lupus 15:94\u2013101","journal-title":"Lupus"},{"key":"7711_CR74","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s10067-016-3366-y","volume":"35","author":"JM Mej\u00eda-Vilet","year":"2016","unstructured":"Mej\u00eda-Vilet JM, C\u00f3rdova-S\u00e1nchez BM, Uribe-Uribe NO, Correa-Rotter R (2016) Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. Clin Rheumatol 35:2219\u20132227","journal-title":"Clin Rheumatol"},{"key":"7711_CR75","doi-asserted-by":"crossref","unstructured":"R. Pe\u00f1a-Vizcarra \u00d3, M.F. Zavala-Miranda, B. Ju\u00e1rez-Cuevas, S.E. M\u00e1rquez-Macedo, A. Hern\u00e1ndez-Andrade, A. Nordmann-Gomes, A.A. P\u00e9rez-Arias, L.E. Morales-Buenrostro and J.M. Mej\u00eda-Vilet, Effect of antimalarials on clinical outcomes in lupus nephritis, Rheumatology (Oxford) (2023).","DOI":"10.1093\/rheumatology\/kead576"},{"key":"7711_CR76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0961203319890007","volume":"29","author":"JS Lee","year":"2020","unstructured":"Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S (2020) Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus 29:52\u201357","journal-title":"Lupus"},{"key":"7711_CR77","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00431-023-04837-0","volume":"182","author":"FS Gheet","year":"2023","unstructured":"Gheet FS, Dawoud HE, El-Shahaby WA, Elrifaey SM, Abdelnabi HH (2023) Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial. Eur J Pediatr 182:1685\u20131695","journal-title":"Eur J Pediatr"},{"key":"7711_CR78","doi-asserted-by":"crossref","unstructured":"V. Andrade Balbi, C. Artur Silva, T. Nascimento Pedrosa, R. Maria Rodrigues Pereira, L. Maria de Arruda Campos, E. Pires Leon, N. Duarte, V. Melechco Carvalho, S. Gofinet Pasoto, D. Cordeiro do Ros\u00e1rio, L. Kolachinski Brandao, I.B. H, E. Bonf\u00e1 and N. Emi Aikawa, Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis, Lupus 31 (2022) 97\u2013104.","DOI":"10.1177\/09612033211062515"},{"key":"7711_CR79","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000089","volume":"2","author":"M Dall'Era","year":"2015","unstructured":"Dall\u2019Era M, Levesque V, Solomons N, Truman M, Wofsy D (2015) Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med 2:e000089","journal-title":"Lupus Sci Med"},{"key":"7711_CR80","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","volume":"61","author":"M Zen","year":"2022","unstructured":"Zen M, Fuzzi E, Loredo Martinez M, Depascale R, Fredi M, Gatto M, Larosa M, Saccon F, Iaccarino L, Doria A (2022) Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford) 61:688\u2013695","journal-title":"Rheumatology (Oxford)"},{"issue":"2009","key":"7711_CR81","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel GJ, Alarcon GS, McGwin G Jr., Danila MI, Zhang J, Bastian HM, Reveille JD, Vila LM, G. Lumina Study (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 61(2009):830\u2013839","journal-title":"Arthritis Rheum"},{"key":"7711_CR82","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s10067-021-05600-2","volume":"40","author":"CB Zanetti","year":"2021","unstructured":"Zanetti CB, Pedrosa T, Kupa LVK, Aikawa NE, Borba EF, Vendramini MBG, Silva CA, Pasoto SG, Bonfa E (2021) Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2\u20133 mg\/kg\/day): 12-month prospective randomized controlled trial. Clin Rheumatol 40:2745\u20132751","journal-title":"Clin Rheumatol"},{"key":"7711_CR83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0961203307086503","volume":"17","author":"A Siso","year":"2008","unstructured":"Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, Testi A, Plaza J, Sentis J, Coca A (2008) Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17:281\u2013288","journal-title":"Lupus"},{"key":"7711_CR84","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1093\/ndt\/gfs122","volume":"27","author":"IG Okpechi","year":"2012","unstructured":"Okpechi IG, Ayodele OE, Jones ES, Duffield M, Swanepoel CR (2012) Outcome of patients with membranous lupus nephritis in Cape Town South Africa. Nephrol Dial Transplant 27:3509\u20133515","journal-title":"Nephrol Dial Transplant"},{"key":"7711_CR85","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10067-014-2527-0","volume":"33","author":"E Pokroy-Shapira","year":"2014","unstructured":"Pokroy-Shapira E, Gelernter I, Molad Y (2014) Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clin Rheumatol 33:649\u2013657","journal-title":"Clin Rheumatol"},{"key":"7711_CR86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.55563\/clinexprheumatol\/ztb9sx","volume":"38","author":"OC Kwon","year":"2020","unstructured":"Kwon OC, Cho YM, Oh JS, Hong S, Lee CK, Yoo B, Kim YG (2020) Factors associated with aggravation of tubulointerstitial damage on repeated biopsies in lupus nephritis patients with treatment failure. Clin Exp Rheumatol 38:239\u2013244","journal-title":"Clin Exp Rheumatol"},{"key":"7711_CR87","doi-asserted-by":"crossref","unstructured":"D. Shao, A.L. Jimenez, M.S. Guerrero, S. Wang and A. Broder, Factors Associated with Worsening Interstitial Fibrosis\/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy, Res Sq (2024).","DOI":"10.21203\/rs.3.rs-3867933\/v1"},{"key":"7711_CR88","unstructured":"Shivani Garg, Tripti Singh, Sarah Panzer and C. Bartels, Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients [abstract], in: Editor (Ed.)^(Eds.), Book Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients [abstract], 2020, pp."},{"key":"7711_CR89","volume":"34","author":"KL Lentine","year":"2020","unstructured":"Lentine KL, Lam NN, Caliskan Y, Alhamad T, Xiao H, Schnitzler MA, Chang SH, Axelrod D, Segev DL, McAdams-DeMarco M, Kasiske BL, Hess GP, Brennan DC (2020) Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: analysis of linked US registry and claims data. Clin Transplant 34:e14118","journal-title":"Clin Transplant"},{"issue":"10","key":"7711_CR90","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/0961203312445230","volume":"21","author":"ZH Zheng","year":"2012","unstructured":"Zheng ZH, Zhang LJ, Liu WX, Lei YS, Xing GL, Zhang JJ, Quan SX, Liu D, Hu DS, Li LL, Liu ZS (2012) Predictors of survival in Chinese patients with lupus nephritis. Lupus 21(10):1049\u20131056","journal-title":"Lupus"},{"key":"7711_CR91","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203317739129","volume":"27","author":"CC Mok","year":"2017","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY (2017) Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus 27:722\u2013727","journal-title":"Lupus"},{"key":"7711_CR92","doi-asserted-by":"crossref","unstructured":"R. Pakchotanon, D.D. Gladman, J. Su and M.B. Urowitz, Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis, Lupus 27 (201) 468\u2013474.","DOI":"10.1177\/0961203317726376"},{"key":"7711_CR93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.010","volume":"74","author":"G Moroni","year":"2016","unstructured":"Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, Zaina B, Tincani A, de Liso F, Matinato C, Grossi C, Gatto M, Castellana P, Limardo M, Meroni PL, Messa P, Ravani P, Mosca M (2016) Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 74:6\u201312","journal-title":"J Autoimmun"},{"key":"7711_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000651","author":"MEB Clowse","year":"2022","unstructured":"Clowse MEB, Eudy AM, Balevic S, Sanders-Schmidler G, Kosinski A, Fischer-Betz R, Gladman DD, Molad Y, Nalli C, Mokbel A, Tincani A, Urowitz M, Bay C, van Noord M, Petri M (2022) Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2021-000651","journal-title":"Lupus Sci Med"},{"key":"7711_CR95","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/09612033211004716","volume":"30","author":"K Bremme","year":"2021","unstructured":"Bremme K, Honkanen S, Gunnarsson I, Chaireti R (2021) The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus. Lupus 30:1031\u20131038","journal-title":"Lupus"},{"key":"7711_CR96","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, Costenbader KH (2015) Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol 67:1577\u20131585","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"7711_CR97","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1440-1797.2011.01456.x","volume":"16","author":"YB Chong","year":"2011","unstructured":"Chong YB, Yap DY, Tang CS, Chan TM (2011) Dyslipidaemia in patients with lupus nephritis. Nephrology (Carlton) 16(2):511\u2013517","journal-title":"Nephrology (Carlton)"},{"key":"7711_CR98","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386\u20131394","journal-title":"Ophthalmology"},{"issue":"2023","key":"7711_CR99","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/imj.15908","volume":"53","author":"JL Fairley","year":"2023","unstructured":"Fairley JL, Nikpour M, Mack HG, Brosnan M, Saracino AM, Pellegrini M, Wicks IP (2023) How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. Intern Med J 53(2023):311\u2013317","journal-title":"Intern Med J"},{"key":"7711_CR100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7326\/M22-2453","volume":"176","author":"RB Melles","year":"2023","unstructured":"Melles RB, Jorge AM, Marmor MF, Zhou B, Conell C, Niu J, McCormick N, Zhang Y, Choi HK (2023) Hydroxychloroquine dose and risk for incident retinopathy: a cohort study. Ann Intern Med 176:166\u2013173","journal-title":"Ann Intern Med"},{"key":"7711_CR101","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41:919\u2013931","journal-title":"Drug Saf"},{"key":"7711_CR102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/RHU.0b013e3181c47ec8","volume":"16","author":"JB Kwon","year":"2010","unstructured":"Kwon JB, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney RJ Jr. (2010) Hydroxychloroquine-induced myopathy. J Clin Rheumatol 16:28\u201331","journal-title":"J Clin Rheumatol"},{"key":"7711_CR103","volume":"61","author":"CY Chew","year":"2020","unstructured":"Chew CY, Mar A, Nikpour M, Saracino AM (2020) Hydroxychloroquine in dermatology: new perspectives on an old drug. Australas J Dermatol 61:e150\u2013e157","journal-title":"Australas J Dermatol"},{"key":"7711_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae217","author":"Z-J Yin","year":"2024","unstructured":"Yin Z-J, Li P, Yu J, Zuo D, Fan H, Li F, Wang J, Gao F, Zhao W, Wang S, Ma S, Wang J (2024) Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clinical features and influencing factors. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keae217","journal-title":"Rheumatology"},{"key":"7711_CR105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.xkme.2021.01.006","volume":"3","author":"S Manabe","year":"2021","unstructured":"Manabe S, Mochizuki T, Sato M, Kataoka H, Taneda S, Honda K, Uchida K, Nitta K (2021) Lupus nephritis and hydroxychloroquine-associated zebra bodies: not just in Fabry disease. Kidney Med 3:442\u2013446","journal-title":"Kidney Med"},{"key":"7711_CR106","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","volume":"72","author":"M Petri","year":"2020","unstructured":"Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW (2020) Hydroxychloroquine blood levels predict Hydroxychloroquine retinopathy. Arthritis Rheumatol 72:448\u2013453","journal-title":"Arthritis Rheumatol"},{"key":"7711_CR107","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","volume":"73","author":"M Petri","year":"2021","unstructured":"Petri M, Konig MF, Li J, Goldman DW (2021) Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol 73:997\u20131004","journal-title":"Arthritis Rheumatol"},{"key":"7711_CR108","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/acr.24155","volume":"73","author":"S Garg","year":"2021","unstructured":"Garg S, Unnithan R, Hansen KE, Costedoat-Chalumeau N, Bartels CM (2021) Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 73:707\u2013716","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7711_CR109","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/ndt\/gfx318","volume":"33","author":"C Cunha","year":"2018","unstructured":"Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, Lightstone L (2018) Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant 33:1604\u20131610","journal-title":"Nephrol Dial Transplant"},{"key":"7711_CR110","first-page":"333","volume":"15","author":"A Neves","year":"2023","unstructured":"Neves A, Viveiros L, Venturelli V, Isenberg DA (2023) Promising experimental treatments for lupus nephritis: key talking points and potential opportunities. Res Rep Urol 15:333\u2013353","journal-title":"Res Rep Urol"},{"key":"7711_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/flupu.2024.1459949","author":"K Kimura","year":"2024","unstructured":"Kimura K, Ayano M, Ota S-I, Kushimoto K, Kimoto Y, Mitoma H, Ono N, Arinobu Y, Akashi K, Horiuchi T, Niiro H (2024) Comparative efficacy and safety of belimumab and hydroxychloroquine in the maintenance phase in patients with systemic lupus erythematosus: a retrospective cohort study. Frontiers in Lupus. https:\/\/doi.org\/10.3389\/flupu.2024.1459949","journal-title":"Frontiers in Lupus"},{"key":"7711_CR112","volume":"16","author":"Y Pan","year":"2024","unstructured":"Pan Y, Le J, Lan L, Wang Y, Liu G, Shen X, Ren P, Chen J, Han F (2024) Hydroxychloroquine Induces Remission for IgA Nephropathy With Mild to Moderate Proteinuria: A Single-Centered Retrospective Analysis. Cureus 16:e53395","journal-title":"Cureus"},{"key":"7711_CR113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.56434\/j.arch.esp.urol.20247701.2","volume":"77","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Liu X, Ye P, Xie C, Kong Y (2024) Efficacy and safety of hydroxychloroquine in patients with IgA nephropathy: a meta-analysis. Arch Esp Urol 77:16\u201324","journal-title":"Arch Esp Urol"},{"key":"7711_CR114","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1016\/j.ekir.2024.09.016","volume":"9","author":"H Yang","year":"2024","unstructured":"Yang H, Sun G, Yang X, Luan J, Jiao C, Song Q, Du F, Zhang B, Wang Y, Kopp JB, Zhou H (2024) Pilot trial of hydroxychloroquine as add-on therapy in patients with membranous nephropathy. Kidney Int Rep 9:3446\u20133454","journal-title":"Kidney Int Rep"},{"key":"7711_CR115","first-page":"145","volume":"16","author":"L Sun","year":"2023","unstructured":"Sun L, Kuang XY, Zhang J, Huang WY (2023) Hydroxychloroquine ameliorates hematuria in children with X-linked Alport syndrome: retrospective case series study. Pharmgenomics Pers Med 16:145\u2013151","journal-title":"Pharmgenomics Pers Med"},{"key":"7711_CR116","volume":"8","author":"S Jain","year":"2024","unstructured":"Jain S, Sangle SR, Kim S, John S, D\u2019Cruz D (2024) Hydroxychloroquine as a potential therapy for ANCA-associated vasculitis. Vessel Plus 8:8","journal-title":"Vessel Plus"},{"key":"7711_CR117","volume":"13","author":"AM Nazir","year":"2021","unstructured":"Nazir AM, Koganti B, Gupta K, Memon MS, Zahid MBA, Kumar VS, Tappiti M, Mostafa JA (2021) Evaluating the use of hydroxychloroquine in treating patients with rheumatoid arthritis. Cureus 13:e19308","journal-title":"Cureus"},{"key":"7711_CR118","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang T, Guo Z, Pu J, Riaz F, Feng R, Fang X, Song J, Liang Y, Wu Z, Pan S, Tang J (2021) The efficiency of hydroxychloroquine for the treatment of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Front Pharmacol 12:693796","journal-title":"Front Pharmacol"},{"key":"7711_CR119","volume":"41","author":"B Vermeer","year":"2024","unstructured":"Vermeer B, Veltkamp M, Raasing LRM, Wind AE, Vorselaars ADM (2024) Hydroxychloroquine monotherapy in sarcoidosis: indications, efficacy, and side effects. Sarcoidosis Vasc Diffuse Lung Dis 41:e2024039","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"7711_CR120","volume":"81","author":"CY Wu","year":"2022","unstructured":"Wu CY, Tan M, Huang JY, Chiou JY, Wei JC (2022) Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus. Ann Rheum Dis 81:e75","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07711-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:00:57Z","timestamp":1761660057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07711-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":120,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7711"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07711-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tarek Carlos Salman-Monte declares consulting fees, honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events, support for attending meetings and\/or travel, and participation on a data safety monitoring board or advisory board from GSK, AstraZeneca, Laboratorios Rubi\u00f3, and Otsuka. Eva M\u00e1rquez declares support for attending meetings and\/or travel from GSK and Otsuka. Eva Rodr\u00edguez-Garc\u00eda declares consulting fees from GSK and Otsuka, and honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events and support for attending meetings and\/or travel from GSK, Otsuka and Terumo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}